IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy
IMvigor130 is a randomized phase III study investigating efficacy of first-line treatment with atezolizumab monotherapy versus atezolizumab in combination with chemotherapy versus chemotherapy monotherapy for advanced or metastatic urothelial carcinoma (mUC). Let Professor Aristotle Bamias present the exciting results presented at ASCO GU 2023 in this MEDtalk.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in